| 26.665 2.085 (8.48%) | 02-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 34.44  |
1-year : | 40.23 |
| Resists | First : | 29.48 |
Second : | 34.44 |
| Pivot price | 23.41 |
|||
| Supports | First : | 24.16 |
Second : | 20.87 |
| MAs | MA(5) : | 23.59 |
MA(20) : | 24.07 |
| MA(100) : | 21.89 |
MA(250) : | 12.03 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 58 |
D(3) : | 39 |
| RSI | RSI(14): 57.7 |
|||
| 52-week | High : | 31.18 | Low : | 1.91 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KOD ] has closed Bollinger Bands are 17.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 27.99 - 28.09 | 28.09 - 28.18 |
| Low: | 23.46 - 23.57 | 23.57 - 23.67 |
| Close: | 26.47 - 26.64 | 26.64 - 26.8 |
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Thu, 19 Feb 2026
Kodiak Sciences (NASDAQ:KOD) Shares Up 10.9% - Should You Buy? - MarketBeat
Wed, 18 Feb 2026
GSA Capital Partners LLP Sells 76,735 Shares of Kodiak Sciences Inc. $KOD - MarketBeat
Fri, 06 Feb 2026
KOD Stock Up 24% in 3 Months: Here's What You Need to Know - TradingView
Fri, 06 Feb 2026
KOD Stock Up 24% in 3 Months: Here's What You Need to Know - Zacks Investment Research
Wed, 04 Feb 2026
Early trial of eye drug KSI-101 reports robust vision gains in MESI - Stock Titan
Wed, 04 Feb 2026
Kodiak Sciences (KOD) Price Target Increased by 11.69% to 31.33 - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 4.7 (%) |
| Held by Institutions | 79.9 (%) |
| Shares Short | 7,130 (K) |
| Shares Short P.Month | 4,670 (K) |
| EPS | -4.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.44 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -47.3 % |
| Return on Equity (ttm) | -208 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -127 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -6.48 |
| PEG Ratio | 0 |
| Price to Book value | 59.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|